SPRB

+ Watchlist + Portfolio

Spruce Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $52.96
52-Week Range: $7.00 – $240.00
Market Cap: $149.41M
P/E (TTM): —
EPS (TTM): -37.93
Dividend Yield: —

Advanced Metrics

Price/Book: 2.06
PEG Ratio: —
Return on Equity: -105.98%
Return on Assets: -40.03%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 9.23
Debt/Equity: 0.09
Total Debt: $7.67M
Free Cash Flow: $-20.65M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $60.78M

SPRB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$10.09M	$4.91M	$0.00
Research & Development	$35.20M	$49.43M	$46.42M	$19.52M
Selling, General & Admin	$12.09M	$12.65M	$14.64M	$16.99M
Operating Expenses	$47.28M	$62.08M	$61.06M	$36.51M
Operating Income	-$47.28M	-$51.99M	-$56.15M	-$36.51M
EBITDA	-$45.69M	-$47.37M	-$52.68M	-$38.85M
Pretax Income	-$46.18M	-$47.92M	-$53.04M	-$38.97M
Net Income	-$46.18M	-$47.92M	-$53.04M	-$38.97M
Diluted EPS	-147.00	-93.00	-96.40	-50.83
Diluted Shares	313694	513469	550146	766598

SPRB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.49M	$96.34M	$38.75M	$48.91M
Current Assets	$83.61M	$102.18M	$44.21M	$52.11M
Total Assets	$85.65M	$103.95M	$45.21M	$53.02M
Current Liabilities	$12.45M	$24.46M	$15.25M	$10.09M
Long-Term Debt	$3.29M	$1.72M	$124.00K	—
Total Debt	$6.32M	$4.61M	$2.77M	$736.00K
Total Liabilities	$17.16M	$27.44M	$16.39M	$10.51M
Retained Earnings	-$149.31M	-$197.23M	-$250.27M	-$289.23M
Shareholders' Equity	$68.49M	$76.51M	$28.82M	$42.52M
Working Capital	$71.16M	$77.72M	$28.96M	$42.03M

SPRB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$41.68M	-$33.27M	-$55.96M	-$33.33M
Capital Expenditure	-$8.00K	-$7.00K	—	—
Free Cash Flow	-$41.69M	-$33.28M	-$55.96M	-$33.33M
Depreciation & Amortisation	$74.00K	$70.00K	$46.00K	$21.00K
Stock-Based Compensation	$3.63M	$4.62M	$5.35M	$2.57M
Investing Cash Flow	$23.69M	$55.78M	$0.00	—
Financing Cash Flow	-$241.00K	$49.14M	-$1.62M	$43.48M
Net Change in Cash	-$18.23M	$71.64M	-$57.59M	$10.15M

SPRB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$10.84M	—	$5.01M	$4.10M	$7.58M
Selling, General & Admin	$3.65M	$3.12M	$3.22M	$7.00M	$4.41M
Operating Expenses	$14.49M	$2.69M	$8.23M	$11.10M	$11.99M
Operating Income	-$14.49M	-$2.69M	-$8.23M	-$11.10M	-$11.99M
EBITDA	-$14.00M	-$2.03M	-$8.19M	-$14.63M	-$11.34M
Pretax Income	-$14.04M	-$2.07M	-$8.21M	-$14.65M	-$12.27M
Net Income	-$14.04M	-$2.07M	-$8.21M	-$14.65M	-$12.27M
Diluted EPS	-23.95	-3.49	-14.58	—	-8.94
Diluted Shares	586142	592618	563066	—	1.37M

SPRB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$25.61M	$16.39M	$10.67M	$48.91M	$54.08M
Current Assets	$30.58M	$20.95M	$14.52M	$52.11M	$55.03M
Total Assets	$31.65M	$21.82M	$15.31M	$53.02M	$56.17M
Current Liabilities	$15.67M	$8.06M	$9.43M	$10.09M	$11.78M
Long-Term Debt	—	—	—	—	$5.46M
Total Debt	$2.29M	$1.82M	$1.35M	$736.00K	$7.12M
Total Liabilities	$16.32M	$8.64M	$9.93M	$10.51M	$21.52M
Retained Earnings	-$264.31M	-$266.38M	-$274.59M	-$289.23M	-$301.50M
Shareholders' Equity	$15.32M	$13.18M	$5.39M	$42.52M	$34.65M
Working Capital	$14.91M	$12.89M	$5.09M	$42.03M	$43.25M

SPRB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.73M	-$8.83M	-$5.32M	-$6.46M	-$8.73M
Capital Expenditure	—	—	—	—	-$10.00K
Free Cash Flow	-$12.73M	-$8.83M	-$5.32M	-$6.46M	-$8.74M
Depreciation & Amortisation	$6.00K	$7.00K	$3.00K	$5.00K	$252.00K
Stock-Based Compensation	$544.00K	-$77.00K	$415.00K	$1.69M	$689.00K
Investing Cash Flow	$0.00	—	—	—	-$10.00K
Financing Cash Flow	-$411.00K	-$400.00K	-$402.00K	$44.69M	$13.92M
Net Change in Cash	-$13.14M	-$9.23M	-$5.72M	$38.24M	$5.17M

Market Snapshot

About

Spruce Biosciences is a biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is advancing tildacerfont, an investigational therapy for patients with congenital adrenal hyperplasia, a rare genetic disorder affecting cortisol production.